Sugi Predict

Sugi Predict / Targets / DEPTOR

DEPTOR

DEP domain-containing mTOR-interacting protein · Q8TB45 · DEPTOR on Sugi Atlas →

646 patent compounds predicted against DEPTOR, 323 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL21327672 SCHEMBL21327672 1.00 5/20
SCHEMBL21327650 SCHEMBL21327650 0.57 5/20
SCHEMBL21327602 SCHEMBL21327602 0.50 5/20
SCHEMBL21327600 SCHEMBL21327600 1.00 4/20
SCHEMBL21327609 SCHEMBL21327609 1.00 4/20
SCHEMBL21327622 SCHEMBL21327622 0.64 4/20
SCHEMBL21327608 SCHEMBL21327608 0.55 4/20
SCHEMBL21327559 SCHEMBL21327559 1.00 3/20
SCHEMBL21327612 SCHEMBL21327612 1.00 3/20
SCHEMBL21327664 SCHEMBL21327664 1.00 3/20
SCHEMBL14799454 SCHEMBL14799454 0.88 3/20
SCHEMBL15438738 SCHEMBL15438738 0.67 3/20
SCHEMBL21327665 SCHEMBL21327665 0.65 3/20
SCHEMBL21327669 SCHEMBL21327669 0.64 3/20
SCHEMBL923847 SCHEMBL923847 0.60 3/20
SCHEMBL21327623 SCHEMBL21327623 0.59 3/20
SCHEMBL21327594 SCHEMBL21327594 1.00 2/20
SCHEMBL21327498 SCHEMBL21327498 0.70 2/20
SCHEMBL21327598 SCHEMBL21327598 0.70 2/20
SCHEMBL21327486 SCHEMBL21327486 0.65 2/20

Clinical trials — most relevant to DEPTOR by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Topical Metformin Emulgel VS Salicylic Acid Peeling in Treatment of Acne Vulgaris PHASE4UNKNOWN
Doxycycline In Lymphangioleiomyomatosis (LAM) PHASE4COMPLETED
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder PHASE2/PHASE3RECRUITING
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety PHASE2COMPLETED
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC) PHASE1/PHASE2COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer PHASE2COMPLETED
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI PHASE2COMPLETED
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study PHASE2RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PHASE1WITHDRAWN
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors PHASE1WITHDRAWN
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer PHASE1ACTIVE_NOT_RECRUITING
Glutamine Supplementation in People With Immune Dysregulation EARLY_PHASE1WITHDRAWN
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy EARLY_PHASE1RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry) nanRECRUITING
Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane nanUNKNOWN
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children nanCOMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy nanRECRUITING
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory nanCOMPLETED
MEHMO Natural History and Biomarkers nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a DEPTOR binder may also engage these)

ProteinNameSimilarity
Q570Y9 — 1.000 Q570Y9 →
P25799 — 0.990 P25799 →
NFKB1 Nuclear factor NF-kappa-B p105 subunit 0.989 landscape →
KAT8 Histone acetyltransferase KAT8 0.989 landscape →
Q5XI06 — 0.987 Q5XI06 →
P70600 — 0.987 P70600 →
Q7Z401 — 0.987 Q7Z401 →
P49802 — 0.987 P49802 →
Q9H1H9 — 0.986 Q9H1H9 →
O12990 — 0.986 O12990 →
O14827 — 0.986 O14827 →
A2CEA7 — 0.986 A2CEA7 →
Q8BX57 — 0.986 Q8BX57 →
PTK2B Protein-tyrosine kinase 2-beta 0.986 landscape →
Q9BXL7 — 0.986 Q9BXL7 →
INPP5B Type II inositol 1,4,5-trisphosphate 5-phosphatase 0.986 landscape →
DCLK1 Serine/threonine-protein kinase DCLK1 0.986 landscape →
D3ZEY4 — 0.986 D3ZEY4 →
Q9DDT2 — 0.986 Q9DDT2 →
KDM5B Lysine-specific demethylase 5B 0.986 landscape →
Q5DU57 — 0.986 Q5DU57 →
Q9NYT0 — 0.986 Q9NYT0 →
Q7Z3E5 — 0.985 Q7Z3E5 →
Q1LYM3 — 0.985 Q1LYM3 →
Q2HJE1 — 0.985 Q2HJE1 →
Q12756 — 0.985 Q12756 →
Q9D3R6 — 0.985 Q9D3R6 →
Q6PGN3 — 0.985 Q6PGN3 →
D3YWQ0 — 0.985 D3YWQ0 →
Q8K337 — 0.985 Q8K337 →